Biohaven reports first quarter 2023 financial results and reports recent business developments

Acquired exclusive license for oral, brain-penetrant, dual tyk2/jak1 inhibitor for immune-mediated brain disorders in march 2023 covering global rights (excluding china) appointed nick kozauer, m.d. as svp of clinical development and regulatory strategy following his tenure as director of the division of neurology 2 in the office of new drugs of the u.s. food and drug administration taldefgrobep alfa granted fast track designation in sma driving strong and consistent progress across six robust drug development platforms in 2023: in kv7 activation, targeting phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023; phase 1 study initiation planned with potentially first-in-class tyk2/jak1 brain-penetrant inhibitor in immune-mediated brain disorders; three phase 3 studies gaining momentum with regulatory engagement and enrollment completion expected in programs spanning glutamate modulation in sca and ocd, respectively, and enrollment ongoing in myostatin inhibition program in sma; three ind submissions anticipated in 2023 spanning kv7 activation, trpm3 antagonism, and igg degradation offer potential to drive long-term value creation beyond 2023 new haven, conn.
BHVN Ratings Summary
BHVN Quant Ranking